Home > Riviste > Minerva Medica > Fascicoli precedenti > Articles online first > Minerva Medica 2020 Sep 21

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

 

Minerva Medica 2020 Sep 21

DOI: 10.23736/S0026-4806.20.06821-4

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Challenges and new perspectives in the treatment of advanced cutaneous squamous cell carcinoma: an expert opinion

Gabriella BRANCACCIO 1, Elvira MOSCARELLA 1, Giulia BRIATICO 1, Pasquale VEROLINO 2, Roberto ALFANO 3, Giuseppe ARGENZIANO 1

1 Dermatology Unit, University of Campania Luigi Vanvitelli, Naples, Italy; 2 Plastic Surgery Unit, Multidisciplinary Department of Medical-Surgical and Dental Specialties, University of Campania Luigi Vanvitelli, Naples, Italy; 3 Department of Anesthesiology, Surgery and Emergency, University of Campania Luigi Vanvitelli, Naples, Italy


PDF


Despite the overall excellent survival rates in patients affected by early cutaneous squamous cell carcinoma (CSCC), advanced forms of CSCC are associated with high patient mortality. To date, only limited therapeutic modalities have been implemented, including chemotherapy and radiotherapy. Systemic therapy was enriched by the addition of epidermal growth factor receptor inhibitors (EGFRi) in the last years. Unfortunately, the overall outcome of all these therapeutic strategies remains poor, therefore important unmet clinical needs persist. Thanks to a better understanding of the biology of advanced CSCC, new treatment options are now available. This article presents the current definition of advanced CSCC along with actual therapeutic options and discusses the strengths and limitations of a new promising systemic approach, which involves the use of immune checkpoint inhibitors.


KEY WORDS: Advanced cutaneous squamous cell carcinoma; Chemotherapy; Radiation therapy; Epidermal growth factor receptor inhibitors; Immune checkpoint inhibitors

inizio pagina